QuidelOrtho Corp
QDEL · XNASCIK 1906324fmd_1XX3W9AMCHMR5BXHX6JMMYEDNHManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Dec 30, 2019 to Sep 27, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 1,662 | 1,699 | 3,266 | 2,998 | 2,783 | 2,730 |
| Net interest income | (9) | (6) | (76) | (148) | (164) | – |
| Research and development | 84 | 96 | 188 | 245 | 219 | 186 |
| Selling, general and administrative | 181 | 240 | 621 | 763 | 767 | 746 |
| Operating income | 1,060 | 906 | 844 | 139 | (1,961) | (919) |
| Interest expense | – | – | 76 | 148 | 164 | 178 |
| Other non-operating income (expense) | (1) | 0 | (8) | (21) | (7) | (6) |
| Income before taxes | 1,040 | 900 | 736 | (29) | (2,132) | (1,108) |
| Income tax expense | 230 | 196 | 187 | (19) | (80) | 24 |
| Net income from continuing operations | 810 | 704 | 549 | (10) | (2,052) | (1,132) |
| Net income | 810 | 704 | 549 | (10) | (2,052) | (1,132) |
| Net income to common shareholders | 811 | 704 | 549 | – | – | – |